ARTICLE | Company News

Gilead, Envision Pharmaceutical Holdings LLC, UnitedHealth Group sales and marketing update

February 2, 2015 8:00 AM UTC

UnitedHealth selected Gilead’s Harvoni ledipasvir/sofosbuvir as its preferred regimen to treat HCV genotype 1 infection. The decision will apply to the payer’s 2015 formulary and will affect insured commercial customers in its Optum Rx pharmacy benefit manager, self-insured customers and its Medicare and Medicaid customers. The payer did not disclose if it would maintain any of the prior restrictions on disease severity it had in place for Harvoni. ...